News

2 More Countries Approve Orladeyo for Preventing HAE Attacks

Regulatory health agencies in Canada and Switzerland have approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) as the first daily oral therapy to prevent hereditary angioedema (HAE) attacks. With these approvals, Orladeyo will be available in the two countries for the routine prevention of HAE attacks in patients ages 12 and…

HAE-associated Mortality in Brazil Tied to Income Levels

Death due to breathing difficulties associated with hereditary angioedema (HAE) remains a concern in Brazil, highlighting that misdiagnosis and a lack of treatment access in lower-income countries may contribute to increased mortality rates, a recent study highlights. While HAE-associated deaths have declined significantly in recent years within high-income countries,…